Lipella Pharmaceuticals (LIPO) versus Its Rivals Head to Head Comparison

Lipella Pharmaceuticals (NASDAQ:LIPO) is one of 1,044 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Lipella Pharmaceuticals to similar businesses based on the strength of its dividends, institutional ownership, valuation, analyst recommendations, profitability, risk and earnings.

Valuation & Earnings

This table compares Lipella Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lipella Pharmaceuticals	$450,000.00	-$4.62 million	-0.52
Lipella Pharmaceuticals Competitors	$9.78 billion	$154.01 million	-5.92

Lipella Pharmaceuticals’ peers have higher revenue and earnings than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 37.0% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Lipella Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-817.16%	-172.07%	-141.17%
Lipella Pharmaceuticals Competitors	-3,565.94%	-254.29%	-30.85%

Risk and Volatility

Lipella Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals’ peers have a beta of 1.00, suggesting that their average stock price is 0% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Lipella Pharmaceuticals and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0	0	1	0	3.00
Lipella Pharmaceuticals Competitors	7497	20681	48124	1166	2.55

Lipella Pharmaceuticals currently has a consensus price target of $2.00, suggesting a potential upside of 538.98%. As a group, “Pharmaceutical preparations” companies have a potential upside of 63.07%. Given Lipella Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Lipella Pharmaceuticals is more favorable than its peers.

Summary

Lipella Pharmaceuticals beats its peers on 8 of the 13 factors compared.

Lipella Pharmaceuticals Company Profile

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.